Your session is about to expire
← Back to Search
pegsitacianine for Peritoneal Carcinomatosis
Study Summary
This trial is testing a new cancer-detecting agent that may help improve outcomes for patients with peritoneal carcinomatosis.
- Peritoneal Carcinomatosis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people are being welcomed into this clinical trial?
"Sixty individuals are needed to complete this study's protocol. These research subjects must meet the required inclusion criteria and can come from different parts of the country, like Winston-Salem, North carolina or Houston, Texas."
What are the potential risks associated with pegsitacianine?
"While there is some data indicating that pegsitacianine is safe, as this is only a Phase 2 trial, efficacy has not been established yet. Therefore, it received a score of 2."
Could you tell me how many hospitals have been selected to test this new medical treatment?
"Currently, this trial is taking place in Winston-Salem, Houston and Pittsburgh as well as 5 other locations. If you are considering enrolling, please note that it may be advantageous to select the clinical site closest to your home."
Are there any patients that have not yet been enrolled in this experiment?
"Yes, according to the listing on clinicaltrials.gov, this study is open for enrollment. The trial was first announced on 11/30/2021 with the most recent update being on 9/19/2022. This research is looking for 60 individuals total at 5 sites."
Share this study with friends
Copy Link
Messenger